Evidence map›Paper›PMID 38753953›Full record

ArticleACS infectious diseases2024

Identification and Validation of Compounds Targeting

Mirtha E Aguado, Sandra Carvalho, Mario E Valdés-Tresanco, De Lin, Norma Padilla-Mejia, Victoriano Corpas-Lopez, Martina Tesařová, Julius Lukeš, David Gray, Jorge González-Bacerio and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mirtha E AguadoCenter for Protein Studies, Faculty of Biology, University of Havana, 10400 Havana, Cuba.
Sandra CarvalhoWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.
Mario E Valdés-TresancoCentre for Molecular Simulations, University of Calgary, Calgary, AB T2N 1N4, Canada.
De LinWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.
Norma Padilla-MejiaWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.ORCID 0000-0001-5492-7926
Victoriano Corpas-LopezWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.
Martina TesařováInstitute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic.
Julius LukešInstitute of Parasitology, Biology Centre, Czech Academy of Sciences, 37005 České Budějovice, Czech Republic.
David GrayWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.
Jorge González-BacerioCenter for Protein Studies, Faculty of Biology, University of Havana, 10400 Havana, Cuba.
Susan WyllieWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.ORCID 0000-0001-8810-5605
Mark C FieldWellcome Centre for Anti-Infective Research, School of Life Sciences, University of Dundee, DD1 4HN Scotland, U.K.ORCID 0000-0002-4866-2885

Funding

Wellcome TrustWellcome Trust 203134/Z/16/ZWellcome Trust 204697/Z/16/ZWellcome Trust 218448/Z/19/Z
6 · The paper itself

Abstract

Leishmaniasis is a neglected tropical disease; there is currently no vaccine and treatment is reliant upon a handful of drugs suffering from multiple issues including toxicity and resistance. There is a critical need for development of new fit-for-purpose therapeutics, with reduced toxicity and targeting new mechanisms to overcome resistance. One enzyme meriting investigation as a potential drug target in

Indexed as

Antiprotozoal AgentsLeishmania majorProtozoan ProteinsAnimalsHumansLeishmania donovaniAntiprotozoal AgentsProtozoan Proteinsdrug discoveryLeishmaniaM17 leucyl-aminopeptidaseRapidFire-MStarget validation

Identifiers

PMID38753953
PMCPMC11184559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.